Education
About Us
Working with TipRanks
Follow Us
Sprint Bioscience AB (DE:5JA1)
FRANKFURT:5JA1
5JA1 Stock Chart & Stats
€0.11
>-€0.01(-2.52%)
At close: 4:00 PM EST
€0.11
>-€0.01(-2.52%)
Day’s Range― - ―
52-Week Range€0.02 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€13.90M
Enterprise Value€49.83M
Total Cash (Recent Filing)€10.95M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Feb 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,515,540
10 Day Avg. Volume250
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)11.75
Price to Sales (P/S)1.66
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
5JA1 FAQ
What was Sprint Bioscience AB’s price range in the past 12 months?
Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.16 in the past 12 months.
What is Sprint Bioscience AB’s market cap?
Sprint Bioscience AB’s market cap is €13.90M.
When is Sprint Bioscience AB’s upcoming earnings report date?
Sprint Bioscience AB’s upcoming earnings report date is Feb 11, 2026 which is in 50 days.
How were Sprint Bioscience AB’s earnings last quarter?
Sprint Bioscience AB released its earnings results on Nov 25, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
Is Sprint Bioscience AB overvalued?
According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued.
Does Sprint Bioscience AB pay dividends?
Sprint Bioscience AB does not currently pay dividends.
What is Sprint Bioscience AB’s EPS estimate?
Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sprint Bioscience AB have?
Sprint Bioscience AB has 105,515,540 shares outstanding.
What happened to Sprint Bioscience AB’s price movement after its last earnings report?
Sprint Bioscience AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 175%.
Which hedge fund is a major shareholder of Sprint Bioscience AB?
Currently, no hedge funds are holding shares in DE:5JA1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sprint Bioscience AB
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
Technical Analysis
2cureX AB
―
Scandinavian ChemoTech AB Class B
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―